Molecular Markers of Glioma Initiation and Progression
神经胶质瘤发生和进展的分子标志物
基本信息
- 批准号:6756565
- 负责人:
- 金额:$ 199.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-06-14 至 2006-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (provided by Applicant)
Gliomas are a significant cause of morbidity and mortality, and thus have been
the focus of frequent basic biologic, basic genetic, and clinical
investigations. Numerous genetic and biologic alterations associated with
gliomas have been described. However, many of the specific genes involved in
gliomas have yet to be identified. A great deal still needs to be learned
about the mechanisms by which the known genes are involved in the pathogenesis
of gliomas. Furthermore, while much has been learned about the biology and
genetics of gliomas, little of this information has been translated into
clinical practice. There are still problems with the morphologic
classification of gliomas - especially oligodendrogliomas and mixed
oligoastrocytomas. It is difficult to predict which patients with anaplastic
astrocytomas will suffer early recurrence. And while some gliomas with
specific genetic alterations seem to respond to chemotherapy (e.g., Cairncross
et al., JNCI 90:1473,1998), these observations need to be confirmed and
extended and additional therapeutic genetic targets identified and/or
developed. Through four projects and two cores this program, which builds on
the past experience of the Glioma Marker Network (GMN) consortium, will study
the basic biology of several specific biochemical and genetic alterations
associated with gliomas. It will also continue to evaluate the predictive,
prognostic, and pathologic relevance of these alterations. Project 1 will
study the biologic and clinical relevance of 7q gain in gliomas, with emphasis
on the mechanism by which this alteration predicts a poorer prognosis.
Project 2 will evaluate the function of mutated and amplified EGFR in gliomas
and will test several potential therapeutic approaches targeting these mutant
receptors. Project 3 will identify and study the function of the 19q gene
associated with gliomas and associated with a prolonged response of some
gliomas to chemotherapy. Project 4 will study the biologic and clinical
relevance of glycolipid and glycosyltransferase alterations in gliomas. Thus,
through these projects, this highly-interactive and experienced program will
make significant progress toward understanding the pathogenesis of gliomas,
and translating this knowledge into new diagnostic and therapeutic tools.
描述:(由申请人提供)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT B. JENKINS其他文献
ROBERT B. JENKINS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT B. JENKINS', 18)}}的其他基金
UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS
了解胶质瘤发病机制中种系和体细胞改变之间的相互作用
- 批准号:
10625788 - 财政年份:2018
- 资助金额:
$ 199.13万 - 项目类别:
(PQ3) UNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMAS
(PQ3) 了解胶质瘤发病机制中种系和体细胞改变之间的相互作用
- 批准号:
10475617 - 财政年份:2018
- 资助金额:
$ 199.13万 - 项目类别:
Identification of 9p and 20q Germline Alterations in Glioblastoma Pathogenesis
胶质母细胞瘤发病机制中 9p 和 20q 种系改变的鉴定
- 批准号:
7814535 - 财政年份:2009
- 资助金额:
$ 199.13万 - 项目类别:
Identification of 9p and 20q Germline Alterations in Glioblastoma Pathogenesis
胶质母细胞瘤发病机制中 9p 和 20q 种系改变的鉴定
- 批准号:
7937827 - 财政年份:2009
- 资助金额:
$ 199.13万 - 项目类别:
Molecular Markers of Glioma Initiation and Progression
神经胶质瘤发生和进展的分子标志物
- 批准号:
6496855 - 财政年份:2001
- 资助金额:
$ 199.13万 - 项目类别:
Molecular Markers of Glioma Initiation and Progression
神经胶质瘤发生和进展的分子标志物
- 批准号:
6607199 - 财政年份:2001
- 资助金额:
$ 199.13万 - 项目类别:
Molecular Markers of Glioma Initiation and Progression
神经胶质瘤发生和进展的分子标志物
- 批准号:
6926925 - 财政年份:2001
- 资助金额:
$ 199.13万 - 项目类别:
相似国自然基金
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
- 批准号:81271563
- 批准年份:2012
- 资助金额:60.0 万元
- 项目类别:面上项目
胶质瘤中miR-93的转录调控及其促细胞周期进展的新机制
- 批准号:81101915
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
- 批准号:81101916
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
胶质瘤中miR-23b介导ICAT负调控β-catenin/TCF4信号通路的新机制
- 批准号:81001128
- 批准年份:2010
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
基因修饰的人脐带间充质干细胞治疗胶质瘤的实验研究
- 批准号:81001009
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
人脑胶质瘤Aurora A基因作用及其分子机制的研究
- 批准号:81072082
- 批准年份:2010
- 资助金额:33.0 万元
- 项目类别:面上项目
胶质瘤中AKT/β-catenin信号转导通路转录调控miR-21的新机制
- 批准号:30971136
- 批准年份:2009
- 资助金额:32.0 万元
- 项目类别:面上项目
生物信息学筛选的miRNA对SEPT7的调控与胶质瘤恶性表型的关系研究
- 批准号:30872985
- 批准年份:2008
- 资助金额:31.0 万元
- 项目类别:面上项目
双向磷酸化调节P38MAPK信号通路在榄香烯抗脑胶质瘤增殖中的作用
- 批准号:30740027
- 批准年份:2007
- 资助金额:10.0 万元
- 项目类别:专项基金项目
Thalidomide增强temozolomide对恶性胶质瘤治疗作用潜在机理的研究
- 批准号:30772228
- 批准年份:2007
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Next Generation Glioma Treatments using Direct Light Therapy
使用直接光疗法的下一代神经胶质瘤治疗
- 批准号:
10092859 - 财政年份:2024
- 资助金额:
$ 199.13万 - 项目类别:
EU-Funded
GlioPrevent: PiezoMagnetic Nanoparticles to Prevent Glioma Invasion in Human Brain Organoids
GlioPrevent:压电磁性纳米颗粒可预防人脑类器官中的神经胶质瘤侵袭
- 批准号:
EP/Y00289X/1 - 财政年份:2024
- 资助金额:
$ 199.13万 - 项目类别:
Research Grant
GLIOMATCH: The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics
GLIOMATCH:恶性胶质瘤免疫肿瘤学媒人:利用空间分辨的放射多组学实现数据驱动的精准医学
- 批准号:
10113516 - 财政年份:2024
- 资助金额:
$ 199.13万 - 项目类别:
EU-Funded
Elucidating the role of tRNA epitranscriptome in Glioma pathology and development of novel therapies
阐明 tRNA 表观转录组在胶质瘤病理学和新疗法开发中的作用
- 批准号:
23K27432 - 财政年份:2024
- 资助金额:
$ 199.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
テクスチャ解析と分子解析に基づく、gliomaの病理診断法の刷新
基于纹理分析和分子分析的胶质瘤创新病理诊断方法
- 批准号:
24K10399 - 财政年份:2024
- 资助金额:
$ 199.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Next Generation Glioma Treatments using Direct Light Therapy (GlioLighT)
使用直接光疗法 (GlioLighT) 的下一代神经胶质瘤治疗
- 批准号:
10110169 - 财政年份:2024
- 资助金额:
$ 199.13万 - 项目类别:
EU-Funded
Elucidating the role of tRNA epitranscriptome in Glioma pathology and development of novel therapies
阐明 tRNA 表观转录组在胶质瘤病理学和新疗法开发中的作用
- 批准号:
23H02741 - 财政年份:2023
- 资助金额:
$ 199.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Synthesis of functional PET probes targeting enzymes specifically expressed in glioma
针对神经胶质瘤中特异性表达的酶的功能性 PET 探针的合成
- 批准号:
23K04929 - 财政年份:2023
- 资助金额:
$ 199.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Deciphering communication networks across glioblastoma cell states
破译胶质母细胞瘤细胞状态的通信网络
- 批准号:
488907 - 财政年份:2023
- 资助金额:
$ 199.13万 - 项目类别:
Operating Grants
Deciphering the molecular & cellular basis of Low-Grade Glioma
破译分子
- 批准号:
478958 - 财政年份:2023
- 资助金额:
$ 199.13万 - 项目类别:
Operating Grants